Capricor Therapeutics Inc To Present 18-Month Data Results From Ongoing HOPE-2 Open Label Extension Transcript
Hi. Good afternoon, and welcome to PPMDs webinar with Capricor Therapeutics. I'm Pat Furlong, and I'm going to be joining the webinar with Linda Marbán and Dr. Craig McDonald. We're here today to talk about CAP-1002 programs in HOPE-1 and HOPE-2 and bring up to date on recruiting for this Phase 3 program.
So with that, I'm going to turn the slides over to Linda and Dr. Craig McDonald. Please begin. (Conference Instructions) Thank you for joining us, Linda?
¡ -
Thank you, Pat. And thank you, PPMD, for giving us this opportunity to provide this update to the community. This webinar primarily focusses on patients and their families to allow you to see the long-term benefits of CAP-1002 in those boys and young men that were in the HOPE-2 enter the HOPE-2 open-label extension trial.
Next slide, please, AJ. We are a publicly traded company. Our symbol is CAPR. And all of our filings are up to date with the SEC,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |